Plasmablastic lymphoma: An update

Plasmablastic lymphoma (PBL) is a highly aggressive B cell non‐Hodgkin lymphoma frequently associated with immunosuppression, particularly human immunodeficiency virus (HIV) infection. Although PBL is rare globally, South Africa has a high burden of HIV infection leading to a higher incidence of PBL...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of laboratory hematology Vol. 44; no. S1; pp. 54 - 63
Main Authors Bailly, Jenique, Jenkins, Nicholas, Chetty, Dharshnee, Mohamed, Zainab, Verburgh, Estelle R., Opie, Jessica J.
Format Journal Article
LanguageEnglish
Published Chichester Wiley Subscription Services, Inc 01.09.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Plasmablastic lymphoma (PBL) is a highly aggressive B cell non‐Hodgkin lymphoma frequently associated with immunosuppression, particularly human immunodeficiency virus (HIV) infection. Although PBL is rare globally, South Africa has a high burden of HIV infection leading to a higher incidence of PBL in the region. Laboratory features in PBL may overlap with plasmablastic myeloma and other large B cell lymphomas with plasmablastic or immunoblastic morphology leading to diagnostic dilemmas. There are, however, pertinent distinguishing laboratory features in PBL such as a plasma cell immunophenotype with MYC overexpression, expression of Epstein–Barr virus‐encoded small RNAs and lack of anaplastic lymphoma kinase (ALK) expression. This review aims to provide a summary of current knowledge in PBL, focusing on the epidemiology, pathophysiology, laboratory diagnosis and clinical management.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1751-5521
1751-553X
DOI:10.1111/ijlh.13863